We identified a subclass of high-risk ALL patients characterized as IL7RhighSH2B3low which is consistent with the reported effect of IL7R and SH2B3 in the oncogenesis of B-ALL [19, 21, 34]. Here, SH2B3 is linked to precursor B-cell acute lymphoblastic leukemia.